Olema Pharmaceuticals, Inc. OLMA 深 滬
等待開盤 06-26 09:30:00 美东时间
11.25
+0.110
+0.99%
華盛通- 最 高11.80
- 今 開11.16
- 成交量 116.39万股
- 最 低 11.095
- 昨 收 11.14
- 總市值 9.83亿
- 52周最高 36.2591
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 4.37
- 委 比 -48.98%
- 總股本 8734.75万
- 歷史最高 60.27
- 量 比 1.01
- 振 幅 6.33%
- 歷史最低 2.00
- 每 手 1
- 風險率 8.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Olema Pharmaceuticals Reports Initial Clinical Data From The Phase 1 Study of OP-3136, A KAT6 Inhibitor, At 2026 ASCO Annual Meeting; OP-3136 Monotherapy Was Well-tolerated With No Dose-limiting Toxicities Observed And No Discontinuations Due To Treatment-related Adverse Events; OP-3136 Shows Evidence Of Anti-tumor Activity Across Multiple Solid Tumor Types
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and
05-22 05:08
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Pharmaceuticals announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and promising anti-tumor activity as a monotherapy across multiple dose levels in various advanced solid tumor types. The study demonstrated tumor shrinkage in over two-thirds of evaluable patients and evidence of on-target engagement, reinforcing confidence in OP-3136 as a potential best-in-class KAT6 inhibitor. The data also s...
05-21 21:00
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35
Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $35.
05-13 21:48
Olema Pharmaceuticals shares are trading lower. The company reported Q1 EPS results.
Olema Pharmaceuticals shares are trading lower. The company reported Q1 EPS res...
05-13 00:46
Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.53) by 1.89 percent. This is a 44.44 percent decrease over losses of $(0.36) per share
05-12 19:44
Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point
Olema Pharmaceuticals ( ($OLMA) ) has shared an update. On April 27, 2026, Olem...
05-02 06:33
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals granted stock options for 188,500 shares to four new employees under its 2022 Inducement Plan, effective April 1, 2026. The options vest over four years with a 10-year term and an exercise price of $15.12 per share.
04-02 20:30
